Skip to content

Physical Capacity in Hodgkin Lymphoma Survivors

Physical Capacity Evaluation and Effects of ExerciseTraining on Hodgkin Lymphoma Survivors

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04636255
Enrollment
40
Registered
2020-11-19
Start date
2017-10-21
Completion date
2023-10-21
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin Lymphoma, Adult, Cardiovascular Diseases, Radiation Effect, Chemotherapy Effect

Keywords

Oxygen Consumption, Physical Training, Heart Hate, Cardioprotection

Brief summary

The study aims to investigate if physical capacity obtained in the cardiopulmonary exercise test can predict cardiovascular alterations in Hodgkin Lymphoma (HL) Survivors. In addition, to study the effects of exercise training on physical capacity and cardiovascular responses in these patients.

Detailed description

Hodgkin Lymphoma (HL) is a hematological neoplasia that mainly affects young people. Anthracycline-based chemotherapy, followed or not by mediastinal radiotherapy, substantially improves prognosis in this set of patients. Observational studies have shown that cardiovascular disease is the most non oncologic cause of death in this population. Coronary artery disease (CAD) affects 26% of survivors after 10 years of absence of HL . However, the early intervention and the assessment to predict the cardiovascular risk remain little known. In this study, the investigators will test the hypothesis that physical capacity can predict the cardiovascular alterations in HL Survivors. In addition, exercise training improves physical capacity and heart rate responses in this set of patients.

Interventions

Body Weight, Height

DIAGNOSTIC_TESTAssessment of Heart rate variability

Holter 24h

DIAGNOSTIC_TESTBlood Pressure and Cardiac Autonomic Control

Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.

DIAGNOSTIC_TESTEvaluation of Baroreflex Control

The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.

DIAGNOSTIC_TESTCardiac Function and Structure

Echocardiogram

DIAGNOSTIC_TESTAssessment of Coronary Anatomy and Calcium Score

Angiotomography

DIAGNOSTIC_TESTBlood Assessments

Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).

DIAGNOSTIC_TESTPhysical Capacity

Cardiopulmonary Exercise Test.

PROCEDUREPhysical Training

Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hodgkin Lymphoma Survivors * Over 18 years old * Chemotherapy with anthracycline and mediastinal radiotherapy in the last 5 years or more

Exclusion criteria

* Renal insufficiency * Pregnant women, * Iodinated contrast allergy, * Life expectancy less than 1 year.

Design outcomes

Primary

MeasureTime frameDescription
Physical Capacity - Peak oxygen consumption (mL/kg/min)4 monthsOxygen consuption in crescent effort will be calculated by aggregation of volume (mL), body weight (Kg) and time (minutes).

Secondary

MeasureTime frameDescription
Heart Hate (beat/min)4 monthsPost-exercise heart rate will be evaluated by the number of beats in time masurement (one minute).
Cardiac Function - Ejection Fraction4 monthsEjection Fraction (EF=ESV-EDV/EDV) combines end systolic (ESV) and diastolic volumes (EDV)(mL)

Countries

Brazil

Contacts

Primary ContactLuciana S Santos
gglusantos@gmail.com551126615043
Backup ContactMarilia RH Santos, PhD
marilia.higuchi@gmail.com551126615043

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026